
Immunome (IMNM) Stock Forecast & Price Target
Immunome (IMNM) Analyst Ratings
Bulls say
Immunome is positioned for success in the biotechnology industry with a strong pipeline of promising drugs such as varegacestat and IM-3050 with positive results in Phase 3 and IND clearance. However, the company also faces risks in terms of financials and regulatory hurdles. With a focus on developing targeted oncology therapies and potential expansion into solid tumors, Immunome offers potential for growth in the long-term.
Bears say
Immunome is a biotechnology company focused on developing targeted oncology therapies and has a strong precision-oncology pipeline. Their lead asset, varegacestat, has shown potential as a top inhibitor for desmoid tumors. However, potential legal action due to side effects and financial risks for the company may pose a challenge. The company's combination therapies and preclinical studies show promise, but more research is needed to fully evaluate the effectiveness of their treatments.
This aggregate rating is based on analysts' research of Immunome and is not a guaranteed prediction by Public.com or investment advice.
Immunome (IMNM) Analyst Forecast & Price Prediction
Start investing in Immunome (IMNM)
Order type
Buy in
Order amount
Est. shares
0 shares